| CEO |
Chang-jae Lee |
- Head of ETC Division,
Daewoong Pharmaceutical
- Head of Marketing Division,
Daewoong Pharmaceutical
- Executive Director, Daewoong
- Executive Vice President,
Daewoong Pharmaceutical
- Chief Executive Officer,
Daewoong Pharmaceutical (Current)
|
Mar 2021 |
Mar 2027 |
Registered |
| Seongsoo Park |
- Medicinal Chemistry Master of Science (MS),
Seoul National Univesity, Korea
- Head of Daewoong America, Inc.
- Head of Nabota Business Division
- Executive Vice President,
Daewoong Pharmaceutical
- Chief Executive Officer,
Daewoong Pharmaceutical (Current)
|
Mar 2024 |
Mar 2027 |
Registered |
| Executive Director |
Eunkyeong Park |
- Head of CH Marketing Division,
Daewoong Pharmaceutical
- Head of ETC Marketing Division,
Daewoong Pharmaceutical
- Executive Director, Daewoong
|
Mar 2024 |
Mar 2027 |
Registered |
| Outside Director |
Dae-duk Kim |
- Director, Research center for endogenous ligand signal transduction modulation anticancer agent(MRC)
- President of Korean Society of Pharmaceutical Sciences and Technology (KSPST) (2018)
- Professor of College of Pharmacy,
Seoul National University,
Korea (Current)
- Fellow member of Korea Academy of Science and Technology (Current)
|
Mar 2022 |
Mar 2025 |
Registered |
| Yong-Jin Kim |
- College of Medicine, Seoul National University, Korea
- MD-Ph.D of Internal Medicine, Seoul National University
- Director of Research Institute / R&DB Foundation, Seoul National University
- Director of Planning Office, Seoul National University
- Professor of Internal Medicine, Seoul National University (Current)
|
Mar 2023 |
Mar 2026 |
Registered |
| Youngmin Cho |
- MD-Ph.D of Internal Medicine,
Seoul National University, Korea
- Visiting professor,
University of British Columbia
- Professor of Internal Medicine,
Seoul National University (Current)
|
Mar 2024 |
Mar 2027 |
Registered |